Related Experiment Video
Updated: May 12, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Multicenter evaluation of patients with cutaneous malignant melanoma in Turkey: MELAS study
Ozlem Uysal-Sonmez1, Ozgur Tanriverdi, Onur Esbah
1Department of Medical Oncology, Sakarya University Education and Research Hospital, Sakarya, Turkey.
Background:
Malignant melanoma is a cancer that demonstrates rapid progression and atypical clinically features with a poor prognosis.
Aim:
This study was performed to determine the clinical characteristics and treatment outcomes of patients with malignant melanoma in Turkey.
Methods:
The medical records of 98 patients between 2007- 2012 at our centers were retrieved from the patient registry. Overall survival (OS) was calculated using the Kaplan-Meier method.
Results:
In our study, with the median follow-up of all patients with cutaneous MM of 46.3 months, the median OS rate of all cases was 43.6 months and 5-year OS was 48.6%. However, five-year OS rates of patients with localized disease (stage I-II) and node involvement (stage III) were 60.3% and 39.6%, respectively. The median OS of stage IV patients was 8.7 months and 1-year OS rate was 26.2%. We showed that advanced stage, male gender, and advanced age in all patients with MM were significant prognostic factors of OS.
Conclusions:
Compared with the results of current studies from Western countries, we found similar findings concerning demographical features, histological variables and survival analyses for our patients with cutaneous MM in Turkey.
